EU GMP Annex 1: sterile manufacturing, CCS and cleanroom grades
EU GMP Annex 1 covers sterile medicinal products. It has been fully applicable since 25 August 2024. What it says on the CCS, grades A to D and monitoring.
EU GMP Annex 1 is the EudraLex Volume 4 guidance on the manufacture of sterile medicinal products, published by the European Commission. It is not an EMA regulation. The revised version was published in August 2022, and the Commission lists it as fully applicable since 25 August 2024.
Most of the revised Annex came into operation on 25 August 2023. One point, 8.123 on lyophilisers, was deferred for a further year, to 25 August 2024. The Commission's announcement gives both implementation dates for the same 2022 revision. The approach is contamination prevention through an integrated contamination control strategy (CCS), qualified processes and monitoring.
What Annex 1 expects from sterile manufacturing
Section 2 prioritises the controls: appropriate design of the facility, equipment and process comes first, then well-designed procedures, then monitoring to show the controls keep working. The Annex states it plainly: "Monitoring or testing alone does not give assurance of sterility."
Section 2.4 adds that microbial, endotoxin/pyrogen and particle controls are interrelated. Their collective effectiveness should be considered together. A CCS is therefore a set of connected controls, not just a monitoring schedule.
The contamination control strategy
The CCS is how those controls are held together and kept under review. Annex 1 does not treat it as a one-off form. Under section 2.3, the CCS should be actively reviewed and updated where appropriate, and it should drive continual improvement. Its effectiveness should be considered as part of periodic management review. Where existing control systems are appropriately managed, they may not need replacing, but the CCS should reference them and the interactions between them should be understood.
What goes into a CCS
Section 2.5 lists elements a CCS should consider. The official section continues past these examples. They include:
- plant and process design, with its documentation
- premises and equipment
- personnel
- utilities
- raw material controls, including in-process controls
- product containers and closures
- vendor approval
Several later sections make the CCS concrete. Controls on a utility should match the product-quality risk from that utility, and the risk assessment should be documented in the CCS (section 6.1). For aseptic processes, the CCS should define acceptance criteria for controls, their monitoring and the review of their effectiveness (section 8.7). Environmental and process monitoring is itself part of the overall CCS (section 9.1). Section 2.6 calls for ongoing and periodic review, and for assessing the impact of system changes on the CCS both before and after implementation.
A practical gap check
For an internal gap check, take each element above and ask: where is the control documented, and who reviews whether it works? Then check how changes feed into the CCS. This is a practical review method, not a regulator-prescribed checklist.
On 25 November 2025 the MHRA published a reminder on Bacillus risks in aseptic processing. It asked sites to review their CCS, with particular attention to material transfer into cleanrooms and to the validation and routine effectiveness of sporicidal sanitisation. That is an inspectorate reminder, not a new Annex 1 revision.
Cleanroom grades A to D
Annex 1 uses four grades, A to D. The table gives examples from the text, not a universal room assignment for every technology.
| Grade | Example operations in Annex 1 |
|---|---|
| A | Aseptic preparation of sterilised product-contact items, filling line setup and sterile filling (section 8.12). For terminally sterilised products, filling when unusually at risk (Table 3). |
| B | Background to Grade A for the aseptic operations in section 8.12. Isolators have their own background provision in section 4.20. |
| C | The minimum grade for filling products destined for terminal sterilisation (section 8.3). Table 3 also gives preparing solutions when unusually at risk. |
| D | Preparation of solutions and components for subsequent filling in terminally sterilised processing (Table 3). |
Aseptic filling and terminal sterilisation do not share one background rule. For the aseptic operations in section 8.12, the work is Grade A with a Grade B background, unless an isolator is used and section 4.20 applies. Terminally sterilised products should be filled in at least Grade C. If the CCS identifies an unusual risk of contamination from the environment, section 8.4 calls for Grade A with at least a Grade C background. Examples in that section include slow filling, wide-necked containers, or containers necessarily exposed for more than a few seconds before closing.
Section 4.3 says restricted access barrier systems (RABS) and isolators are beneficial in reducing contamination from direct human interventions in the critical zone. Their use should be considered in the CCS, and any alternative approach should be justified. For isolator backgrounds, section 8.12 refers to section 4.20. Check that provision rather than applying the Grade B background rule to every system.
Classification, qualification and monitoring
Classification and routine monitoring use different tables for different purposes. Classification is part of cleanroom qualification. Under section 4.27, total particles at or above 0.5 µm and 5 µm are measured both at rest and in simulated operations, against the limits in Table 1. Requalification has maximum intervals of six months for Grades A and B and twelve months for Grades C and D (requalification provisions). Those are maximums. Changes or loss of control can trigger requalification earlier.
Routine monitoring is a separate activity. Section 9.9 points to Table 5 for maximum total particle action limits and Table 6 for maximum viable particle action limits. Sites may set tighter action limits based on trends, the nature of the process or the CCS. Alert levels should be based on qualification results and reviewed against ongoing trend data. Don't reuse the Table 1 classification values as monitoring limits. Take the numbers from the official tables themselves.
In Grade A, total particle monitoring should cover the full duration of critical processing, including equipment assembly (section 9.16), and section 9.17 calls for continuous monitoring at both particle sizes. Continuous viable air monitoring in Grade A should cover critical processing, including aseptic setup (section 9.24). A similar approach should be considered for Grade B, based on the risk to aseptic processing.
In Grades C and D, in-operation monitoring should use qualification and routine data for effective trend analysis. Action limits depend on the operations performed and may be tighter than Table 5 and Table 6 (section 9.12).
Section 9.1 explains how to assess these results together. Viable monitoring, non-viable monitoring and aseptic process simulation (APS) each have limited reliability on their own, and none of them should be treated as an indicator of asepsis by itself. Taken together, the results help confirm that the design, validation and operation of the system being monitored are reliable.
Personnel and aseptic process simulation
Under section 7.4, staff entering Grade A and B areas should be trained in aseptic gowning and behaviour. Gowning compliance should be assessed and reassessed at least annually, with both visual and microbial assessment. Unsupervised access to Grade A and B areas where aseptic operations are or will be conducted should be restricted to appropriately qualified personnel who have passed the gowning assessment and participated in a successful APS.
Periodic APS should normally be repeated twice a year, approximately every six months, for each aseptic process, each filling line and each shift. Each operator should take part in at least one successful APS a year (section 9.38). That annual figure is not the rule for manual aseptic operations. Section 9.39 says that where manual operation, such as aseptic compounding or filling, occurs, each container type, container closure and equipment train should be initially validated with each operator taking part in at least three consecutive successful APS, then revalidated with one APS approximately every six months for each operator.
Lyophilisers and point 8.123
Point 8.123 is the part that came in a year late. It covers lyophiliser design as well as sterilisation frequency. Lyophilisers and the associated product transfer and loading and unloading areas should be designed to minimise operator intervention as far as possible. Sterilisation frequency should be set from the design and the risks of system contamination during use. Lyophilisers that are manually loaded or unloaded, with no barrier technology separation, should be sterilised before each load. Where loading and unloading are automated, or protected by closed barrier systems, the frequency should be justified and documented in the CCS (point 8.123). It does not require sterilisation before every load for all lyophilisers.
Where to get the official text, and UK and US context
The official Annex 1 is on the Commission's EudraLex Volume 4 page, listed as "Manufacture of Sterile Medicinal Products". The official PDF contains the detailed provisions. Use it for the numeric tables, the complete section 2.5 list and the grade definitions in section 4.
In the UK, the MHRA lists EU Volume 4 among its GMP guidance resources. UK manufacturers should check MHRA requirements and the GMP guidance that applies to their authorisation, rather than assume the EU publication alone sets every obligation.
In the US, the FDA's aseptic processing guidance helps manufacturers meet the requirements of 21 CFR Parts 210 and 211. Annex 1 is not an FDA regulation, and EU grades should not be assumed to map one-to-one onto US cleanroom classifications.
RegAffairs AI's answer on Annex 1 covers the CCS and cleanroom-grade questions with source citations.